Precision medicine is an emerging approach to healthcare where genetic or molecular analysis is used to match patients with the most appropriate treatment for their specific disease. Earlier this summer Konica Minolta announced an agreement to purchase genetic testing and analysis company Ambry Genetics Corporation (“Ambry”). This is another move by Konica Minolta to accelerate development of its exciting new medical platform to advance precision medicine, discover new therapeutic targets and develop new technologies and therapeutics. Invicro built these services on a software and analytics platform enabling streamlined large-scale data analytics across any quantitative biomarker readout. Invicro is a global Contract Research Organization (CRO) providing imaging services to the pharmaceutical and biotechnology industry from early phase discovery through late-phase clinical trials. (“Konica Minolta”) (TOKYO: 4902 ISIN: JP3300600008) and Boston-based Invicro LLC (“Invicro”) today announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development. ![]() - Other Countries (MiddleEast) / English.- Other Countries (AsiaPacific) / English. ![]() - Other Countries (Americas) / English.
0 Comments
Leave a Reply. |